NCT02828358 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02828358
Title	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	National Cancer Institute (NCI)
Indications	acute leukemia B-cell acute lymphoblastic leukemia
Therapies	Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine
Age Groups:	child
Covered Countries	USA \| CAN \| AUS

Additional content available in CKB BOOST